In vivo 18F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy

M Malpetti, SS Kaalund, KA Tsvetanov… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder characterized by
neuroglial tau pathology. A new staging system for PSP pathology postmortem has been …

[HTML][HTML] 18F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy

FT Liu, JY Lu, XY Li, XN Liang, FY Jiao, JJ Ge… - European Journal of …, 2023 - Springer
Purpose Human post mortem studies have described the topographical patterns of tau
pathology in progressive supranuclear palsy (PSP). Recent advances in tau PET tracers are …

[HTML][HTML] Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy

A Ishiki, R Harada, H Kai, N Sato, T Totsune… - Acta neuropathologica …, 2018 - Springer
Recent positron emission tomography (PET) studies have demonstrated the accumulation of
tau PET tracer in the affected region of progressive supranuclear palsy (PSP) cases. To …

18F-PI-2620 tau PET improves the imaging diagnosis of progressive supranuclear palsy

K Messerschmidt, H Barthel, M Brendel… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy movement disorder that can
be imaged by the 18F-labeled tau PET tracer 2-(2-([18F] fluoro) pyridin-4-yl)-9 H-pyrrolo [2, 3 …

[HTML][HTML] Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy

M Song, M Scheifele, H Barthel, T van Eimeren… - European journal of …, 2021 - Springer
Purpose Dynamic 60-min positron emission tomography (PET) imaging with the novel tau
radiotracer [18 F] PI-2620 facilitated accurate discrimination between patients with …

[HTML][HTML] [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy

M Brendel, S Schönecker, G Höglinger… - Frontiers in Aging …, 2018 - frontiersin.org
Progressive supranuclear palsy (PSP) is a neurodegenerative movement disorder
characterized by deposition of fibrillar aggregates of 4R tau-protein in neurons and glial …

18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study

DR Schonhaut, CT McMillan, S Spina… - Annals of …, 2017 - Wiley Online Library
Objective 18F‐flortaucipir (formerly 18F‐AV1451 or 18F‐T807) binds to neurofibrillary
tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in …

[HTML][HTML] 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty

JL Hsu, SH Chen, IT Hsiao, CS Lu, TC Yen… - Scientific Reports, 2020 - nature.com
The associations of 18F-THK5351 tau positron emission tomography (PET) findings with
core domains of progressive supranuclear palsy (PSP) and its diagnostic certainty have yet …

[HTML][HTML] 18F-flortaucipir tau PET distinguishes established progressive supranuclear palsy from controls and Parkinson's disease: a multicenter study

DR Schonhaut, CT McMillan, S Spina… - Annals of …, 2017 - ncbi.nlm.nih.gov
Objective 18 F-flortaucipir (formerly 18 F-AV1451 or 18 F-T807) binds to neurofibrillary
tangles in Alzheimer's disease (AD), but tissue studies assessing binding to tau aggregates …

Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy

M Brendel, H Barthel, T van Eimeren, K Marek… - JAMA …, 2020 - jamanetwork.com
Importance Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific
tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future …